Valneva receives first chikungunya vaccine approval after two month delay to FDA review
Valneva received the first regulatory approval for a chikungunya virus vaccine with an FDA accelerated nod on Thursday night.
The green light marks a key win for the European biotech, which will get more than a year’s head start on potential competitor Bavarian Nordic and could snag about $100 million by selling the priority review voucher that it gets as part of the approval. It also serves as a boon to Valneva as the company works through hurdles with another of its late-stage investigational vaccines for Lyme disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.